Clinical Question
In adults with medication-refractory chronic rhinitis, does blue-laser inferior turbinate reduction combined with blue-laser posterior nasal nerve neurolysis improve nasal symptom scores without serious complications?
Explore This Issue
November 2026Bottom Line
In adults with chronic rhinitis and confirmed allergic rhinitis who had failed more than three months of medical therapy, combined blue-laser inferior turbinate reduction (BITR) plus blue-laser posterior nasal nerve neurolysis (BPN3) produced large and sustained improvements in 24-hour reflective Total Nasal Symptom Score (rTNSS) and Nasal Obstruction Symptom Evaluation (NOSE) scores at one and six months. There were no serious complications, and dual-layer nerve modulation with BPN3 plus turbinate reduction offered superior symptom relief with excellent safety and tolerability. Dual-layer nerve modulation offers a promising minimally invasive option for medication-refractory chronic allergic rhinitis.
Background: Chronic rhinitis (allergic, nonallergic, or mixed) affects more than 26.3% of people in Taiwan and causes rhinorrhea, congestion, itching, and sneezing. Medical therapy (topical/systemic agents) is first-line, but surgeons consider options when symptoms persist. Traditional vidian neurectomy carries risks such as bleeding, crusting, numbness, and eye dryness. Office-based posterior nasal nerve (PNN) ablation using cryotherapy or temperature-controlled radiofrequency has emerged elsewhere, but such devices are not widely available in many Asian countries.
Study Design: Retrospective single-center study in 2025 including 42 adults (18-65 years) with chronic rhinitis and nasal congestion refractory to more than three months of intranasal steroid and antihistamine therapy. All patients had elevated IgE confirming allergic rhinitis, total 24-hour rTNSS >5, moderate-to-severe rhinorrhea, and mild-to-severe congestion. Blue-laser inferior turbinate reduction plus BPN3 was performed, and rTNSS and NOSE scores were recorded at baseline, one month, and six months post-operatively.
Setting: Outpatient endoscopic surgery at Shuang Ho Hospital, Taipei Medical University, Taiwan, using a 445-nm blue laser for posterior nasal neurolysis and inferior turbinate reduction.
Synopsis: All 42 patients underwent dual-layer nerve modulation: superficial PNN plexus treatment at the lateral posterior middle meatus and the posterior ends of the middle and inferior turbinates, followed by deep submucosal ablation of the main nerve trunks at the posterior middle and inferior turbinates. Blue-laser inferior turbinate reduction was then performed with a 2.5 W super-pulse contact blue laser applied submucosally to the anterior one-third of the inferior turbinate to debulk tissue while preserving mucosa. At baseline, mean rTNSS was 7.9 ± 2.1 and NOSE was 69.3 ± 11.4. At one month, mean rTNSS fell to 1.8 ± 1.7 (about −78.5%) and NOSE to 7.0 ± 6.5 (about −89.9%), and at six months rTNSS was 1.9 ± 1.8 (about −76.0%) and NOSE 6.6 ± 5.3 (about −92.0%). Crusting was described as minor and transient, and no serious complications were observed during the study period. The authors emphasize that the 445-nm blue laser’s photoangiolytic properties allow bloodless, accurate tissue ablation in the vascular posterior nasal region, and that dual-layer nerve modulation addresses both superficial plexuses and deep trunks in the extensively distributed PNN fibers. BPN3 combined with BITR attains both safety and effectiveness and represents a promising minimally invasive treatment for medication-refractory chronic allergic rhinitis.
Citation: Li LJ, et al. Blue-laser posterior nasal neurolysis via dual layer nerve modulation for chronic rhinitis. Laryngoscope Investig Otolaryngol. 2026;11:e70468. doi:10.1002/lio2.70468.
Leave a Reply